



29th March 2021

Circular 009/21

Dear Pharmacist,

From 1st May 2021, the HSE will reimburse the notified reference price for the relevant interchangeable PrEP products (Emtricitabine/Tenofovir disoproxil 200 mg/245 mg Film-coated Tablets) that have administrative codes as detailed below.

Product	Pack Size	Administration Code	Reimbursement Price
Emtricitabine and Tenofovir Disoproxil 200/245 mg (MYLAN)	30	77100	€48.60
Emtricitabine and Tenofovir Disoproxil 200/245 mg (TEVA)	30	77101	€48.60
Emtricitabine and Tenofovir Disoproxil 200/245 mg (ROWEX)	30	77102	€48.60
Emtricitabine and Tenofovir Disoproxil 200/245 mg (ACCORDPHARMA)	30	77105	€48.60
Emtricitabine and Tenofovir Disoproxil 200/245 mg (CLONMEL)	30	77107	€48.60

Interchangeable List Code: IC0107-165-003

Pharmacies can claim for these products for approved patients electronically using the relevant administrative claiming codes, submitting with monthly claims. Patient approval can be confirmed through the 'Eligibility Confirmation' on the Pharmacy Suite under 'Patient Specific Arrangements'.

For patients with PPSNs who cannot continue to full DPS eligibility due to their status in this country (usually students from Non-EU countries), pharmacies can contact Pharmacy Function (Phone: 01-8647100) or email pharmacy.response@hse.ie who will confirm the patients' approved status. I refer to Circular 44/19 in this regard.

Reimbursement claims submitted for patients who are not approved for reimbursement will not be paid.

Yours faithfully,

Shaun Flanagan,
Primary Care Reimbursement & Eligibility.